Johnson & Johnson shared that its medical technology businesses – Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS – will now go by the name Johnson & Johnson MedTech. This is the next step of Johnson & Johnson’s updated brand and visual identity announced in September 2023.
This move underscores Johnson & Johnson’s leadership in medical technology with a focus on cardiovascular, orthopaedic, surgery and vision solutions. Today’s announcement has no impact on the medical technology products and solutions currently offered to customers.
Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, issued the following statement on this change:
“At Johnson & Johnson, we are addressing some of the largest unmet needs in healthcare through innovative medicine and medical technology. By bringing our medtech businesses together under the Johnson & Johnson name, the scale of our impact in healthcare will be even more apparent, unlocking new opportunities for us to strengthen our competitiveness.
“While Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and CERENOVUS will now go by Johnson & Johnson MedTech, we will continue to honor the legacies of these brands by maintaining the products, services and approach to collaboration that made them some of the most trusted names in healthcare.”
Partners, customers and consumers will begin to see the change come to life on social media channels and marketing materials over the coming weeks. The updated brand and visual identity will have no impact on the Johnson & Johnson MedTech portfolio.
